Trending...
- Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 292
- Q4 2025 Outlook: JGCMGS Unveils High-Frequency Infrastructure for Italian and Global Markets
- AI, Fintech, and Cybersecurity Divisions Ignite High-Margin Growth: IQSTEL, Inc. (N A S D A Q: IQST)
RALEIGH, N.C., April 16, 2021 /PRNewswire/ -- Contego Medical, Inc., a leading developer of innovative cardiovascular devices, today announced receipt of CE Mark approval for the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System).
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
The patented Neuroguard IEP System contains a novel, next-generation nitinol stent, a pre-positioned post-dilation balloon and an integrated microembolic filter with 40 μm pores. The closed cell stent is designed to achieve optimal performance across radial strength, vessel coverage and flexibility, additionally featuring a unique asymmetric hourglass design that is flared at both ends to facilitate wall apposition in tortuous anatomy. The integrated filter is designed to capture both macro- and micro-emboli during the entire procedure. The Neuroguard IEP System is indicated for adult patients with clinically significant carotid artery stenosis requiring stenting.
More on ncarol.com
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
The Neuroguard IEP System was first evaluated in the PERFORMANCE I clinical trial. The study was conducted in nine European sites and included 67 patients with one year follow-up. The overall success rate was 100% with a stroke and death rate of 0% at 30 days1.
"CE Marking of the Neuroguard IEP System is an important milestone for Contego Medical and allows us to bring the remarkable safety and performance benefits of the Neuroguard stent to patients in Europe," said Ravish Sachar, M.D., CEO and Founder of Contego Medical. "We anticipate launching the product in select countries as well initiating a post-marketing clinical study in the coming months."
Stacy Enxing Seng, Venture Partner, Lightstone Ventures, and Contego Medical Board Chair commented "Receipt of CE Mark approval for the Neuroguard IEP System is a significant achievement for the Contego Medical team and represents a multi-year investment in innovative product development and high-quality clinical research. I believe that the Neuroguard IEP System has the performance and ease of use to become the standard of care in the treatment of carotid artery disease."
More on ncarol.com
- High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
About Contego Medical
Contego Medical, Inc. is a medical device company dedicated to the development of novel medical devices for cardiovascular and peripheral vascular procedures. The company's Integrated Embolic Protection (IEP) platform, which combines embolic protection and treatment into one device, is designed to simplify catheter-based procedures and improve patient outcomes.
In the United States, the Neuroguard IEP System is an investigational device, limited by United States law to investigational use.
Neuroguard IEP and the Contego Medical logo are registered trademarks of Contego Medical, Inc. The Neuroguard System is covered by U.S. patents 9,968,472 and 10,932,929 and European patent EP 3,367,967. Additional US and Foreign patents pending.
1 LINC 2020
SOURCE Contego Medical, Inc.
Filed Under: Business
0 Comments
Latest on ncarol.com
- Dr. Johnny Shanks, As Seen on TV, Announces 20% Off Dental Implant Treatments | Tennessee's Leading All-on-X Provider
- Star Sleep & Wellness Expands to Pearland, Texas — Bringing Life-Changing Sleep Care to More Communities
- Fort Lauderdale Dentist Dr. Taskonak & IN A DAY SMILE Receive Emmy Nomination for Life-Changing Documentary "The Weight of a Smile"
- Men's Health Network Highlights Major 2025 Achievements & Launches New Donation Platform For Greater Impact
- BET and Soul Train Awards - GONE! - Introducing The World Hip Hop Awards
- Australian Aboriginal Cultural Immersions and First Nations Workshops
- Soccer777 to Launch "Enjoy Soccer, Welcome the World Cup" Limited Edition Theme Soccer Set
- Uk Financial Ltd Featured In New York Business Now — 2019 Gold-Backed Bitcoin Prediction Now Becomes SEC Security Token Filing
- MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread
- The NoNickel Gift Guide: Stylish, Skin-Safe Gifts Under $50 (and One Worth the Splurge)
- AI, Fintech, and Cybersecurity Divisions Ignite High-Margin Growth: IQSTEL, Inc. (N A S D A Q: IQST)
- Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders
- Q4 2025 Outlook: JGCMGS Unveils High-Frequency Infrastructure for Italian and Global Markets
- UK Financial Ltd Announces Full Ecosystem To Erc-3643 "SEC-Ready" Tokens For All UK Financial Ltd Tokenized Projects
- Pushing the Wave Series Launches Premium Hardback Editions of 2017–2022 and 2023 Volumes
- ZEELOOL 2025 Black Friday and Cyber Monday Big Deals
- Americans Are Building Family Legacies That Last Generations — Not Just Paychecks That Last a Month
- A $7 Ticket Could Rewrite Someone's Destiny — 327 Acres of U.S. Land to Be Won by Anyone, Anywh
- Bent Danholm Lists Contemporary Lakefront Residence in Winter Garden's Avalon Cove
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm